#STXS

Fazen Capital

@fazencapital.bsky.social

2 days ago

Stereotaxis Wins FDA Clearance for Synchrony System Stereotaxis cleared by FDA on Apr 6, 2026; STXS stock moved up ~8% intraday. Synchrony targets the U.S. ablation market with ~100k–150k annual AF procedures.

Stereotaxis Wins FDA Clearance for Synchrony System: Stereotaxis cleared by FDA on Apr 6, 2026; STXS stock moved up ~8% intraday. Synchrony targets the U.S. ablation market with ~100k–150k annual AF procedures. 👈 Read full analysis #Stereotaxis #FDAClearance #SynchronySystem #CatheterAblation #STXS

StockTitan

@stocktitan.net

2 days ago

Stereotaxis Announces FDA Clearance and Launch of Synchrony System Stereotaxis (NYSE: STXS) announced FDA 510(k) clearance and commercial launch of the Synchrony system on April 6, 2026. Synchrony is a 55" 4K interventional lab display with ultra-low latency video, obsolescence protection, and cloud-based SynX for HIPAA/GDPR-compliant remote collaboration.The company reiterated guidance of over $3 million in 2026 revenue from Synchrony placements independent of robotic systems and emphasized future AI-enabled applications and broader cath lab adoption.

#STXS Stereotaxis Announces FDA Clearance and Launch of Synchrony System

www.stocktitan.net/news/STXS/stereotaxis-an...

StockTitan

@stocktitan.net

4 weeks ago

Stereotaxis Reports 2025 Full Year Financial Results Stereotaxis (NYSE: STXS) reported 2025 results: revenue $32.4M (up 20% YoY) and Q4 revenue $8.6M (up 36% YoY). Recurring revenue was $22.2M (up 21%) and system revenue $10.2M (up 18%). Gross margin was ~53% for full year; cash was $13.4M with no debt.Company highlighted US and EU approvals for GenesisX, MAGiC, and MAGiC Sweep and provided 2026 guidance targeting >$40M revenue and double-digit growth.

#STXS Stereotaxis Reports 2025 Full Year Financial Results

www.stocktitan.net/news/STXS/stereotaxis-re...

Small Cap Strategist

@smcapstrategist.bsky.social

2 months ago

Small-cap stocks in new uptrend with ave directional index, Thu Jan 8th - #SCHL #UCTT #VRA #WHWK #XBIT #EGGF #FLYX #GPUS #SACH #STXS #ALLO #BAER #CRML #FRPL #KLXE #MBUU #OTGA #POWI #RCAT #WKC #VAC #SCM #RES #OIS #HUYA #FPI #DDD #BHR - More: crystalequityresearch.com/leading-indi... - #smallcap

StockTitan

@stocktitan.net

3 months ago

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter Stereotaxis (NYSE: STXS) announced FDA approval on January 6, 2026 of the MAGiC™ Magnetic Interventional Ablation Catheter for robotic cardiac electrophysiology procedures.The MAGiC catheter is robotically navigated for mapping, diagnostic pacing, and creating endocardial lesions to treat supraventricular tachycardia in patients with congenital heart disease when conventional manual navigation is limited.The company highlighted MAGiC's precision, expanded access for complex/underserved patients, and prior global use of Stereotaxis technology in over 150,000 patients.

#STXS Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

www.stocktitan.net/news/STXS/stereotaxis-re...

StockTitan

@stocktitan.net

4 months ago

Stereotaxis Reports 2025 Third Quarter Financial Results Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2025. “We continue to focus on driving commercial

#STXS Stereotaxis Reports 2025 Third Quarter Financial Results

www.stocktitan.net/news/STXS/stereotaxis-re...

StockTitan

@stocktitan.net

4 months ago

GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance Stereotaxis (NYSE: STXS) announced U.S. FDA 510(k) clearance for its new robotic system, GenesisX, on November 10, 2025. GenesisX preserves Robotic Magnetic Navigation while improving accessibility through built-in magnetic shielding, operation on standard 120/230V power, no structural anchoring, and an 80% smaller system cabinet, enabling installation in existing non-modified cath labs.Stereotaxis has started a limited launch in the United States and Europe, is expanding compatible catheters and imaging compatibility, and is preparing supply chain, manufacturing, installation, and commercial processes for a full launch. GenesisX offers flexible capital models including sales, leases, and pay-per-use.

#STXS GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance

www.stocktitan.net/news/STXS/genesis-x-robo...

StockTitan

@stocktitan.net

5 months ago

Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs Stereotaxis (NYSE: STXS) announced on Oct 15, 2025 that it obtained CE Mark in Europe and submitted a 510(k) application to the FDA for the Synchrony system, a platform designed to modernize interventional cath labs. Synchrony pairs a 55" 4K display with latency video digitization and is offered with SynX, a cloud app that the company says is HIPAA and GDPR compliant for remote connectivity, collaboration, recording, and monitoring. The company positions the platforms as foundational for future AI, remote procedures, and improved lab workflows.

#STXS Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs

www.stocktitan.net/news/STXS/stereotaxis-an...

StockTitan

@stocktitan.net

6 months ago

4,500+ Robot-Assisted Heart Procedures: Erasmus MC Advances Cardiac Care with New Genesis Robotic System Erasmus Medical Center introduces Stereotaxis Genesis Robotic System for cardiac ablation, marking Dutch first. Center completed 4,500+ robotic procedures, targeting arrhythmia treatment for complex cases.

#STXS Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System

www.stocktitan.net/news/STXS/erasmus-medica...

StockTitan

@stocktitan.net

7 months ago

First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter Stereotaxis (NYSE: STXS) has achieved a significant milestone with the completion of the world's first procedures using MAGiC Sweep™, their pioneering robotically-navigated high-density electrophysiology mapping catheter. The procedures were successfully performed at Deborah Heart and Lung Center in New Jersey.The MAGiC Sweep catheter demonstrated key advantages including accurate mapping of complex anatomy, stable cardiac tissue contact, clear electrogram signals, and absence of ventricular ectopy. Following recent FDA clearance, Stereotaxis has begun the commercial launch in the United States, while European regulatory clearance is pending.This breakthrough represents a major advancement in robotic electrophysiology, with the technology already used to treat over 150,000 patients globally across the United States, Europe, and Asia.

#STXS First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter

www.stocktitan.net/news/STXS/first-us-comme...

StockTitan

@stocktitan.net

7 months ago

150,000 Patients Treated: Stereotaxis Robotic Surgery Tech Takes Center Stage at HRX 2025 Conference Stereotaxis CEO and leading electrophysiologists to discuss robotic surgery advances at HRX 2025 in Atlanta. Company's technology has treated over 150,000 patients globally.

#STXS Stereotaxis Technology to be Featured at Heart Rhythm Society’s HRX 2025

www.stocktitan.net/news/STXS/stereotaxis-te...

StockTitan

@stocktitan.net

8 months ago

Stereotaxis Reports 2025 Second Quarter Financial Results Stereotaxis (NYSE: STXS), a pioneer in surgical robotics, reported its Q2 2025 financial results with significant growth. Total revenue reached $8.8 million, up 95% year-over-year and 18% sequentially. System revenue was $3.0 million, while recurring revenue grew 35% to $5.8 million.The company achieved a notable milestone with FDA clearance of MAGiC Sweep, its first interventional catheter approval in nearly 20 years. Gross margin was 52%, with recurring revenue margin at 68% and system margin at 22%. The quarter ended with $7.0 million in cash, subsequently strengthened by a $12.5 million strategic financing in July.Management reiterated expectations of double-digit revenue growth for 2025, projecting $2-3 million quarterly system revenue and recurring revenue scaling to $7 million by Q4 2025.

#STXS Stereotaxis Reports 2025 Second Quarter Financial Results

www.stocktitan.net/news/STXS/stereotaxis-re...

StockTitan

@stocktitan.net

8 months ago

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter Stereotaxis (NYSE:STXS), a pioneer in surgical robotics, has received FDA 510(k) clearance for its MAGiC Sweep™ catheter, the world's first robotically navigated high-density electrophysiology mapping catheter. The innovative device features 20 electrodes for detailed cardiac mapping and integrates with Stereotaxis' Robotic Systems.The MAGiC Sweep catheter offers significant advantages including efficient high-density mapping, extended reach and precision, atraumatic design, and improved anatomical accuracy. This marks Stereotaxis' first FDA clearance for an interventional catheter in nearly 20 years and represents a crucial milestone in the company's comprehensive innovation strategy for advancing robotics in electrophysiology.

#STXS Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter

www.stocktitan.net/news/STXS/stereotaxis-re...

StockTitan

@stocktitan.net

8 months ago

Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has announced a $12.5 million registered direct offering of common stock at $2.00 per share. The offering is led by a strategic industry partner and select institutional investors.The financing will be completed in two closings: an initial $8.5 million closing around July 18, 2025, and a second $4.0 million closing by November 25, 2025. Lake Street Capital Markets LLC serves as the exclusive placement agent. The proceeds will support product commercialization, research and development, and other corporate purposes.Stereotaxis technology has been used to treat over 150,000 patients globally across the United States, Europe, Asia, and other regions.

#STXS Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock

www.stocktitan.net/news/STXS/stereotaxis-an...

StockTitan

@stocktitan.net

9 months ago

First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology Stereotaxis (NYSE: STXS), a pioneer in surgical robotics, announced the publication of first clinical results for its MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. The prospective multi-center study demonstrated an impressive 94% acute efficacy rate in treating various heart arrhythmias.The study, conducted at Copenhagen University Hospital Rigshospitalet and Vilnius University Hospital Santaros Klinikos, included 67 patients with various arrhythmias. The average procedure time was 83 minutes skin-to-skin, with a low procedure-related adverse event rate of 1.5%. Patient enrollment continues with approximately 100 patients enrolled to date, with efficacy assessments ongoing for up to one year.The MAGiC catheter, designed for robotically-navigated magnetic ablation procedures, showed notable improvements in stability, eliminating the need for sheaths for catheter support. The technology has already been utilized in treating over 150,000 patients across leading hospitals globally.

#STXS First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology

www.stocktitan.net/news/STXS/first-clinical...

StockTitan

@stocktitan.net

10 months ago

Stereotaxis Reports 2025 First Quarter Financial Results Stereotaxis (NYSE: STXS) reported Q1 2025 financial results with total revenue of $7.5 million, up 9% year-over-year. Recurring revenue grew 29% to $5.5 million, while system revenue decreased to $2.0 million from $2.6 million. The company reported a net loss of $5.8 million and ended the quarter with $10.7 million in cash and no debt. Key highlights include initial MAGiC commercialization in Europe, successful GenesisX demonstrations, and progress on regulatory efforts. Management reiterated expectations for double-digit revenue growth in 2025, projecting system revenue of $2-3 million per quarter and recurring revenue scaling to $7 million by Q4. The company maintains six active regulatory reviews and anticipates significant adoption of GenesisX pending regulatory approval.

#STXS Stereotaxis Reports 2025 First Quarter Financial Results

www.stocktitan.net/news/STXS/stereotaxis-re...

StockTitan

@stocktitan.net

11 months ago

Game-Changing Robotic Surgery System GenesisX Debuts Live: 80% Smaller, Zero Special Requirements Discover how the compact GenesisX transforms cardiac procedures with built-in shielding and table-fitting design. First public demonstration reveals groundbreaking features. See details.

#STXS Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025

www.stocktitan.net/news/STXS/stereotaxis-to...

StockTitan

@stocktitan.net

1 year ago

NVIDIA Backs Stereotaxis: AI-Powered Surgical Robots Transform Healthcare at GTC 2024 Surgical robotics pioneer Stereotaxis gains NVIDIA's backing for AI integration. With 150,000+ treatments completed, this partnership accelerates next-gen medical robotics development.

#STXS Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program

www.stocktitan.net/news/STXS/stereotaxis-hi...

StockTitan

@stocktitan.net

1 year ago

Can Stereotaxis Revolutionize Stroke and Cancer Treatment? New Robotic Catheter Heads to FDA Stereotaxis submits EMAGIN 5F catheter to FDA, expanding robotic navigation into stroke, cancer, and cardiovascular treatments with European submission following.

#STXS Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery

www.stocktitan.net/news/STXS/stereotaxis-su...

StockTitan

@stocktitan.net

1 year ago

Could This First-Ever Robotic Mapping Catheter Transform Cardiac Procedures? MAGiC Sweep offers 20-electrode mapping, enhanced safety, and improved access to difficult cardiac regions, with commercial launch expected in H2 2025.

#STXS Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance

www.stocktitan.net/news/STXS/stereotaxis-su...

StockTitan

@stocktitan.net

1 year ago

Can Stereotaxis Turn Q4 Momentum Into Sustained Growth After Flat 2024 Results? Q4 revenue up 39% YoY with positive cash flow of $1.3M. Full-year revenue reached $26.9M with $15.2M system backlog entering 2025. Company forecasts stronger growth ahead.

#STXS Stereotaxis Reports 2024 Full Year Financial Results

www.stocktitan.net/news/STXS/stereotaxis-re...

StockTitan

@stocktitan.net

1 year ago

Game-Changing Medical Robot Fits Under OR Table: European Hospital First to Order Stereotaxis' Compact GenesisX European hospital orders Stereotaxis' compact GenesisX surgical robot, featuring built-in shielding and 80% smaller footprint. CE Mark approved, system runs on standard power with no room modifications.

#STXS Stereotaxis Announces First GenesisX Robotic System Order

www.stocktitan.net/news/STXS/stereotaxis-an...

StockTitan

@stocktitan.net

1 year ago

Stereotaxis Secures Crucial NMPA Approval for Revolutionary Magnetic Ablation Catheter in China Stereotaxis partners with MicroPort EP for groundbreaking Magbot™ catheter approval in China, featuring advanced magnetic navigation for precise cardiac treatments.

#STXS Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China’s NMPA

#stocks #news #StockMarket

www.stocktitan.net/news/STXS/magbot-robotic...

StockTitan

@stocktitan.net

1 year ago

Stereotaxis Debuts New GenesisX Robot System at World's Largest Radiology Forum | STXS Stock News Stereotaxis showcases its advanced GenesisX robotic navigation system alongside Neusoft Medical's technology at RSNA 2024, marking a significant collaboration in medical robotics.

#STXS Stereotaxis’ GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems

#investing #news #StockMarket

www.stocktitan.net/news/STXS/stereotaxis-ge...

StockTitan

@stocktitan.net

1 year ago

#STXS Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/STXS/stereotaxis-to...

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NYSE: #STXS ) Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China

#StockMarket #News

StockTitan

@stocktitan.net

1 year ago

#STXS Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China

www.stocktitan.net/news/STXS/stereotaxis-ge...

StockTitan

@stocktitan.net

1 year ago

#STXS Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

www.stocktitan.net/news/STXS/hospital-da-lu...